The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zheng, Zhi Guo ^a,b   Xu, Hong ^a   Suo, Sha Sha ^a   Xu, Xiao Li ^a   Ni, Mao Wei ^b   Gu, Lin Hui ^b   Chen, Wei ^b   Wang, Liang Yan ^a   Zhao, Ye ^a   Tian, Bing ^a   Hua, Yue Jin ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GLUTATHIONE; H19 LONG NON-CODING RNA; LONG UNTRANSLATED RNA;

DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GLUTATHIONE; HUMANS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RNA, LONG NONCODING;

EID: 84970029015     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26093     Document Type: Article

References (56)

1. Coleman, M. P. et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377, 127-38 (2011).
2. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11, 719-25 (2011).
3. Berns, E. M. & Bowtell, D. D. The changing view of high-grade serous ovarian cancer. Cancer Res 72, 2701-4 (2012).
4. Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384, 1376-88 (2014).
5. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-83 (2012).
6. Katano, K. et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62, 6559-65 (2002).
7. Holzer, A. K., Katano, K., Klomp, L. W. & Howell, S. B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10, 6744-9 (2004).
8. Borst, P., Evers, R., Kool, M. & Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92, 1295-302 (2000).
9. Breier, A., Gibalova, L., Seres, M., Barancik, M. & Sulova, Z. New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 13, 159-70 (2013).
10. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489-94 (2015).
11. Godwin, A. K. et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89, 3070-4 (1992).
12. Jamali, B. et al. Intracellular GSH Alterations and Its Relationship to Level of Resistance following Exposure to Cisplatin in Cancer Cells. Iran J Pharm Res 14, 513-9 (2015).
13. Martin, L. P., Hamilton, T. C. & Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14, 1291-5 (2008).
14. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-20 (2008).
15. Williams, J. et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96, 287-95 (2005).
16. Yu, H. et al. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer 47, 1585-94 (2011).
17. Liu, Y. & Lu, X. Non-coding RNAs in DNA damage response. Am J Cancer Res 2, 658-75 (2012).
18. Huarte, M. et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142, 409-19 (2010).
19. Prensner, J. R. et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74, 1651-60 (2014).
20. Fan, Y. et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 281, 1750-8 (2014).
21. Wang, F. et al. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma 62, 432-8 (2015).
22. Hao, Y., Crenshaw, T., Moulton, T., Newcomb, E. & Tycko, B. Tumour-suppressor activity of H19 RNA. Nature 365, 764-7 (1993).
23. Yang, F. et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J 279, 3159-65 (2012).
24. Matouk, I. J. et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2, e845 (2007).
25. Barsyte-Lovejoy, D. et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 66, 5330-7 (2006).
26. Luo, M. et al. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 333, 213-21 (2013).
27. Ma, C. et al. H19 promotes pancreatic cancer metastasis by derepressing let-7′ s suppression on its target HMGA2-mediated EMT. Tumour Biol 35, 9163-9 (2014).
28. Li, H. et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5, 2318-29 (2014).
29. Zhang, L. et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis 34, 577-86 (2013).
30. Doyle, L. A., Yang, W., Rishi, A. K., Gao, Y. & Ross, D. D. H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 56, 2904-7 (1996).
31. Tsang, W. P. & Kwok, T. T. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 26, 4877-81 (2007).
32. Matouk, I. J. et al. Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys Acta 1843, 1414-26 (2014).
33. Jin, L. et al. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Mol Cell Proteomics 13, 3138-51 (2014).
34. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-11 (2009).
35. Cabili, M. N. et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 25, 1915-27 (2011).
36. Flicek, P. et al. Ensembl 2013. Nucleic Acids Res 41, D48-55 (2013).
37. Yang, C. et al. Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. Oncotarget 6, 15311-20 (2015).
38. Verhaegh, G. W. et al. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol 54, 1118-26 (2008).
39. Cai, X. & Cullen, B. R. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 13, 313-6 (2007).
40. Tsang, W. P. et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31, 350-8 (2010).
41. Keniry, A. et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol 14, 659-65 (2012).
42. Meijer, C. et al. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52, 6885-9 (1992).
43. Chen, H. H. & Kuo, M. T. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010 (2010).
44. Ishikawa, T. & Ali-Osman, F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268, 20116-25 (1993).
45. Dedoussis, G. V. & Andrikopoulos, N. K. Glutathione depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to Natural Killer cell-mediated cell death via necrosis rather than apoptosis. Eur J Cell Biol 80, 608-14 (2001).
46. Matouk, I. J. et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 1803, 443-51 (2010).
47. Hou, X. et al. 3′, 4′, 5′, 5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway. Mol Cells 38, 396-401 (2015).
48. Chen, H. H. et al. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol 74, 697-704 (2008).
49. Tsukamoto, N., Chen, J. & Yoshida, A. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells Mol Dis 24, 231-8 (1998).
50. McLellan, L. I. & Wolf, C. R. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updat 2, 153-164 (1999).
51. Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12, 931-47 (2013).
52. Sporn, M. B. & Liby, K. T. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12, 564-71 (2012).
53. Ariel, I. et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 53, 320-3 (2000).
54. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28, 511-5 (2010).
55. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNASeq. Nat Methods 5, 621-8 (2008).
56. Chen, W., Zhao, Y., Seefeldt, T. & Guan, X. Determination of thiols and disulfides via HPLC quantification of 5-thio-2-nitrobenzoic acid. J Pharm Biomed Anal 48, 1375-80 (2008).